Voxel-wise analysis of [123I]β-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease

Brain

Volumn 128, Issue 7, 2005, Pages 1605-1612

  Scherfler, Christoph ^a   Seppi, Klaus ^a   Donnemiller, Eveline ^a   Goebel, Georg ^a   Brenneis, Christian ^a   Virgolini, Irene ^a   Wenning, Gregor K ^a   Poewe, Werner ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

123I CIT SPECT; Discriminant analysis; Idiopathic Parkinson's disease; Multiple system atrophy; Statistical parametric mapping

Indexed keywords

2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)TROPANE I 123; RADIOISOTOPE; UNCLASSIFIED DRUG; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; CARRIER PROTEIN; COCAINE; DIAGNOSTIC AGENT; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; DRUG DERIVATIVE; MEMBRANE PROTEIN; NERVE PROTEIN; RADIOPHARMACEUTICAL AGENT; SLC6A3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRAIN SIZE; CAUDATE NUCLEUS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DISCRIMINANT ANALYSIS; DISEASE DURATION; DOPAMINERGIC ACTIVITY; FEMALE; HUMAN; HYPOTHESIS; IDIOPATHIC DISEASE; IMAGE ANALYSIS; LINEAR SYSTEM; MALE; MESENCEPHALON; MONOAMINERGIC SYSTEM; NEUROIMAGING; NEUROPATHOLOGY; PARAMETRIC TEST; PARKINSON DISEASE; PARTITION COEFFICIENT; PRIORITY JOURNAL; PUTAMEN; QUANTITATIVE ANALYSIS; RECEPTOR DENSITY; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL ANALYSIS; STATISTICAL PARAMETRIC MAPPING; STATISTICAL SIGNIFICANCE; STRIATE CORTEX; VOXEL WISE ANALYSIS; CASE CONTROL STUDY; CORPUS STRIATUM; DIFFERENTIAL DIAGNOSIS; METABOLISM; MIDDLE AGED; SCINTISCANNING; STATISTICAL MODEL;

AGED; CASE-CONTROL STUDIES; CAUDATE NUCLEUS; COCAINE; CORPUS STRIATUM; DIAGNOSIS, DIFFERENTIAL; DISCRIMINANT ANALYSIS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; LINEAR MODELS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MESENCEPHALON; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; NERVE TISSUE PROTEINS; PARKINSON DISEASE; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 21944438870     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awh485     Document Type: Article

References (42)

1. Antonini A, Leenders KL, Vontobel P, Maguire RP, Missimer J, Psylla M, Gunther I. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997; 120: 2187-95.
2. Boja JW, Patel A, Caroll FI, Rahman MA, Philip A, Lewin AH, et al. [125]-RTI55: a potent ligand for dopamine transporters. Eur J Pharmacol 1991; 194: 133-4.
3. Braune S, Reinhardt M, Schnitzer R, Riedel A, Lucking CH. Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology 1999; 53: 1020-5.
4. Brenneis C, Seppi K, Schocke MF, Muller J, Luginger E, Bosch S, et al. Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. Mov Dis 2003; 18: 1132-8.
5. Brooks DJ, Ibanez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28: 547-55.
6. Bruecke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wober C, et al. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I]beta-CIT and SPECT. Correlation with clinical findings and comparision with multiple system atrophy and progressive supranuclear palsy. J Neural Trans Suppl 1997; 50: 9-24.
7. Eckert T, Eidelberg D. The role of functional neuroimaging in the differential diagnosis of idiopathic Parkinson's disease and multiple system atrophy. Clin Auton Res 2004; 14: 84-91.
8. Eckert T, Sailer M, Kaufmann J, Schrader C, Peschel T, Bodammer N, et al. Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. Neurolmage 2004; 21: 229-35.
9. Fahn S, Elton RL, Members of the Unified Parkinson's Disease Rating Scale Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson's disease. Vol. 2. Florham Park (NJ): Macmilian Healthcare Information; 1987. p. 153-64.
10. Friston KJ, Ashburner J, Frith CD, Poline JB, Heather JD, Frackowiak RS. Spatial registration and normalization of images. Hum Brain Mapp 1995; 3: 165-89.
11. Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 1983; 305: 137-8.
12. Gilman S, Low P, Quinn N, Albanese A, Ben-Shlomo Y, Fowler C, et al. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res 1998; 8: 359-62.
13. Glover G, Pelc N. The nonlinear partial volume artefact. J Comput Assisted Tomogr 1979; 25: 79-86.
14. Hesse S, Henryk B, Schwarz I, Sabri O, Müller U. Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders. Neurosci Biobehav Rev 2004; 28: 547-63.
15. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42.
16. Hoffman EJ, Huang SC, Phelps ME. Quantification in positron emission tomography. 1. Effect of object size. J Comput Assist Tomogr 1979; 22: 324-33.
17. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accurancy of clinical diagnosis of idiopathic Parkinson's disease: a cliniopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
18. Innis R, Baldwin R, Sybirska E, Zea Y, Laruelle M, al-Tikriti M, et al. Single photon emission computed tomographic imaging of monoamine reuptake sites in primate brain with [123I]CIT. Eur J Pharmacol 1991; 299: 369-70.
19. Juh R, Kim J, Moon D, Choe B, Suh T. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. Eur J Radiol 2004; 51: 223-33.
20. Kojima A, Matsumoto M, Takahashi M, Hirota Y, Yoshida H. Effect of spatial resolution on SPECT quantification values. J Nucl Med 1989; 30: 508-14.
21. Kuikka JT, Bergstrom KA, Ahonen A, Lansimies E. The dosimetry of iodine-123 labelled 2 beta-carboxymethoxy-3 beta (4-iodophenyl)tropane. Eur J Nucl Med 1994; 21: 53-6.
22. Laruelle M, Wallace E, Seibyl JP, Baldwin RM, Zea Ponce Y, Zoghbi SS, et al. Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta- CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994; 14: 982-94.
23. Neumeyer JL, Wang SY, Milius RA, Baldwin RM, Zea-Ponce Y, Hoffer PB, et al. [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in the brain. J Med Chem 1991; 34: 3144-6.
24. Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 1994; 117: 235-43.
25. Pirker W, Asenbaum S, Kasper S, Walter H, Angelberger P, Koch G, et al. β-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm Gen Sect. 1995; 100: 247-56.
26. Pirker W, Asenbaum S, Bencsits G, Praxer D, Gerschlager W, Deecke L, et al. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 2000a; 15: 1158-67.
27. Pirker W, Asenbaum S, Hauk M, Kandlhofer S, Tauscher J, Willeit M, et al. Imaging serotonin and dopamine transporters with iodine-123-beta-CIT-SPECT: binding kinetics and effects of normal aging. J Nucl Med 2000b; 41: 36-44.
28. Pirker W, Djamshidian S, Asenbaum S, Gerschlager W, Tribl G, Hoffmann M, et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 2002; 17: 45-53.
29. Poewe W, Scherfler C. Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice. Mov Disord 2003; 18: S16-21.
30. Rakshi JS, Uema T, Ito K, Bailey DL, Morrish PK, Ashburner J, et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease: a 3D [18F]dopa-PET study. Brain 1999; 122: 1637-50.
31. Scherfler C, Khan NL, Pavese N, Eunson L, Graham E, Lees AJ, et al. Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain 2004; 127: 1332-42.
32. Schocke MFH, Seppi K, Esterhammer R, Kremser C, Jaschke W, Poewe W, et al. Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. Neuroimage 2004; 21: 1443-51.
33. Schulz JB, Klockgether T, Petersen D, Jauch M, Mueller-Schauenburg W, Spieker S, Voigt K, Dichgans J. Multiple system atrophy: natural history, MRI morphometry, and dopamine receptor imaging with [123I] IBZM-SPECT. J Neurol Neurosurg Psychiatry 1994; 57: 1047-56.
34. Schulz JB, Skalej M, Wedekind D, Luft AR, Abele M, Voigt K, et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1999; 45: 65-74.
35. Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi S, Zea-Ponce Y, et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995; 38: 589-98.
36. Staley JK, Basle M, Flynn DD, Mash DC. Visualizing dopamine and serotonin transporters in the human brain with the potent cocaine analogue [25I]RTI-55: in vitro binding and autoradiographic characterization. J Neurochem 1994; 62: 549-56.
37. Uhl GR. Neurotransmitter transporter: a promising new gene family. Trends Neurosci 1992; 15: 265-8.
38. Van Laere K, Santens P, Bosman T, De Reuck J, Mortelmans L, Dieckx R. Statistical parametric mapping of 99mTc-ECD SPECT in idiopathic Parkinson's disease and multiple system atrophy with predominant parkinsonian features: correlation with clinical parameters. J Nucl Med 2004; 45: 933-42.
39. Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. [123I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord 2001; 16: 1023-32.
40. Wenning GK, Tison F, Ben-Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997, 12: 133-47.
41. Wenning GK, Colosimo C, Geser F, Poewe W. Recent advances in multiple system atrophy. Lancet Neurology 2004; 3: 93-103.
42. Whone AL, Moore RY, Piccini P, Brooks DJ. Plasticity of the nigropallidal pathway in Parkinson's disease. Ann Neurol 2003; 53: 206-13.